Global N-acetylaspartate declines even in benign multiple sclerosis

American Journal of Neuroradiology

Volumn 32, Issue 1, 2011, Pages 204-209

  Rigotti, D J ^a   Gonen, O ^a   Grossman, R I ^a   Babb, J S ^a   Falini, A ^b   Benedetti, B ^b   Filippi, M ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE INJURY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADOLESCENT; ADULT; ASPARTIC ACID; BRAIN; DOWN-REGULATION; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MULTIPLE SCLEROSIS; PROTONS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 78651501631     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2254     Document Type: Article

References (45)

1. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Wilson JD, Martin JB, et al, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1994:2287-95
2. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:S6-11
3. Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: Evidence for different clinical cohorts initial observations. Radiology 2002;225:261-68
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey-National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
6. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: A review. Acta Neurol Scand 2006;113:359-69
7. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol 2004;56:303-06
8. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am 2008;18:589-622
9. Rovaris M, Barkhof F, Calabrese M, et al. MRI features of benign multiple sclerosis: Toward a new definition of this disease phenotype. Neurology 2009; 72:1693-701
10. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-52
11. Costelloe L, Thompson A, Walsh C, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008;79:1245-48
12. Strasser-Fuchs S, Enzinger C, Ropele S, et al. Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox? Mult Scler 2008;14:205-11
13. Ramsaransing G, Maurits N, Zwanikken C, et al. Early prediction of a benign course of multiple sclerosis on clinical grounds: A systematic review. Mult Scler 2001;7:345-47
14. Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal appearing brain tissueMTRhistogram abnormalities. Mult Scler 2003;9:566-73
15. Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue injury in benign MS: A 3T multiparametric MRI study. Neuroimage 2008;39:1499-509
16. Rovaris M, Riccitelli G, Judica E, et al. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology 2008;71:1521-26
17. Thompson AJ, Miller DH, MacManus DG, et al. Patterns of disease activity in multiple sclerosis. BMJ 1990;301:44-45
18. Brass SD, Narayanan S, Antel JP, et al. Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004;31:225-28
19. Audoin B, Guye M, Reuter F, et al. Structure ofWMbundles constituting the working memory system in early multiple sclerosis: A quantitative DTI tractography study. Neuroimage 2007;36:1324-30
20. Jbabdi S, Woolrich MW, Andersson JL, et al. A Bayesian framework for global tractography. Neuroimage 2007;37:116-29
21. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin Neurol 1998;18:327-36
22. Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901
23. Arnold DL, De Stefano N, Narayanan S, et al. Axonal injury and disability in multiple sclerosis: Magnetic resonance spectroscopy as a measure of dynamic pathological change in white matter. In: Comi G, ed. Magnetic Resonance Spectroscopy in Multiple Sclerosis. Milan, Italy: Springer-Verlag Italia; 2001:61-67
24. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-31, discussion S43-54
25. Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate: Neurobiology and clinical significance. Neurology 2008;70:1353-57
26. Mainero C, De Stefano N, Iannucci G, et al. Correlates ofMSdisability assessed in vivo using aggregates of MR quantities. Neurology 2001;56:1331-34
27. Mathiesen HK, Jonsson A, Tscherning T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006;63:533-36
28. Enzinger C, Ropele S, Strasser-Fuchs S, et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol 2003;60:65-70
29. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407-19
30. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-37
31. Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825-29
32. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology 2007;68:496-500
33. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85
34. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: A comparison with conventional T2-weighted images. J Neurol 1997;244:266-70
35. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17: 479-89
36. Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: Quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684-89
37. Benedetti B, Rigotti DJ, Liu S, et al. Reproducibility of the whole-brain Nacetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007;28:72-75
38. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology 2006;66:1384-89
39. Gonen O, Oberndorfer TA, Inglese M, et al. Reproducibility of three wholebrain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2007;28:267-71
40. Benedetti B, Rovaris M, Rocca M, et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009;15:789-94. Epub 2009 May 22
41. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342-52
42. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70
43. Pelletier J, Audoin B, Reuter F, et al. Plasticity in MS: From functional imaging to rehabilitation. Int MS J 2009;16:26-31
44. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: A new measure of disease load in MS. Neurology 2000;54:15-19
45. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(pt 6):1419-28 (Pubitemid 20024212)